These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17082511)

  • 1. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy.
    Dziadziuszko R; Holm B; Skov BG; Osterlind K; Sellers MV; Franklin WA; Bunn PA; Varella-Garcia M; Hirsch FR
    Ann Oncol; 2007 Mar; 18(3):447-52. PubMed ID: 17082511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
    Cappuzzo F; Hirsch FR; Rossi E; Bartolini S; Ceresoli GL; Bemis L; Haney J; Witta S; Danenberg K; Domenichini I; Ludovini V; Magrini E; Gregorc V; Doglioni C; Sidoni A; Tonato M; Franklin WA; Crino L; Bunn PA; Varella-Garcia M
    J Natl Cancer Inst; 2005 May; 97(9):643-55. PubMed ID: 15870435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
    J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
    J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
    Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J
    J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.
    Hirsch FR; Herbst RS; Olsen C; Chansky K; Crowley J; Kelly K; Franklin WA; Bunn PA; Varella-Garcia M; Gandara DR
    J Clin Oncol; 2008 Jul; 26(20):3351-7. PubMed ID: 18612151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR.
    Wang F; Fu S; Shao Q; Zhou YB; Zhang X; Zhang X; Xue C; Lin JG; Huang LX; Zhang L; Zhang WM; Shao JY
    J Transl Med; 2013 Apr; 11():90. PubMed ID: 23557218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.
    Dziadziuszko R; Merrick DT; Witta SE; Mendoza AD; Szostakiewicz B; Szymanowska A; Rzyman W; Dziadziuszko K; Jassem J; Bunn PA; Varella-Garcia M; Hirsch FR
    J Clin Oncol; 2010 May; 28(13):2174-80. PubMed ID: 20351332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes in elderly with advanced-stage non-small cell lung cancer.
    Tam TC; Ho JC; Wong MK; Wong WM; Wang JK; Lam JC; Lui MM; Lam WK; Ip MS; Lam DC
    Lung; 2013 Dec; 191(6):645-54. PubMed ID: 23929397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
    Park S; Choi YL; Sung CO; An J; Seo J; Ahn MJ; Ahn JS; Park K; Shin YK; Erkin OC; Song K; Kim J; Shim YM; Han J
    Histol Histopathol; 2012 Feb; 27(2):197-207. PubMed ID: 22207554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib.
    Buckingham LE; Coon JS; Morrison LE; Jacobson KK; Jewell SS; Kaiser KA; Mauer AM; Muzzafar T; Polowy C; Basu S; Gale M; Villaflor VM; Bonomi P
    J Thorac Oncol; 2007 May; 2(5):414-22. PubMed ID: 17473657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.
    Azuma K; Okamoto I; Kawahara A; Taira T; Nakashima K; Hattori S; Kinoshita T; Takeda M; Nakagawa K; Takamori S; Kuwano M; Ono M; Kage M
    J Thorac Oncol; 2012 Jan; 7(1):122-7. PubMed ID: 21892099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients.
    Pan JB; Hou YH; Zhang GJ
    Clin Lab; 2014; 60(9):1439-47. PubMed ID: 25291939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.